PEG
50
6
AVB
64
2
SYY
62
2
JCI
47
3
A
43
2
MSI
57
5
MTB
55
2
WM
76
2
PNC
50
2
AFL
63
3
SYF
69
2
ESS
57
6
FDX
61
13
IPG
61
11
AAL
42
7
MDLZ
79
10
SBUX
52
3
PBI
40
5
WYNN
45
4
CL
61
3
PEG
50
6
AVB
64
2
SYY
62
2
JCI
47
3
A
43
2
MSI
57
5
MTB
55
2
WM
76
2
PNC
50
2
AFL
63
3
SYF
69
2
ESS
57
6
FDX
61
13
IPG
61
11
AAL
42
7
MDLZ
79
10
SBUX
52
3
PBI
40
5
WYNN
45
4
CL
61
3
Financhill
Back

Beam Therapeutics 10K Form

Sell
30

BEAM
Beam Therapeutics

Last Price:
24.10
Seasonality Move:
24.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-08 10Q BEAM/Beam Therapeutics Quarterly
2023-08-08 10Q BEAM/Beam Therapeutics Quarterly
2023-05-10 10Q BEAM/Beam Therapeutics Quarterly
2022-11-07 10Q BEAM/Beam Therapeutics Quarterly
2022-08-09 10Q BEAM/Beam Therapeutics Quarterly
2022-05-09 10Q BEAM/Beam Therapeutics Quarterly

Receive BEAM News And Ratings

See the #1 stock for the next 7 days that we like better than BEAM

BEAM Financial Statistics

Sales & Book Value

Annual Sales: $377.71M
Cash Flow: $131.48M
Price / Cash Flow: 0
Annual Sales: $12.02
Price / Book: 2.01

Profitability

EPS (TTM): -1.90000
Net Income (TTM): $-132.53M
Gross Margin: $1.48B
Return on Equity: -16.29%
Return on Assets: -9.78%

Beam Therapeutics Earnings Forecast

Key Beam Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for BEAM is 58.08%.
  • The Selling, General & Administrative Expenses for BEAM have been equal to 30.93% of Gross Profit Margin.
  • The Research & Development expenses have been 115.80% of Revenue.
  • The Interest Expense is -0.24% of Operating Income.
  • The Net Earning history of BEAM is -35.09% of Total Revenues.
  • Per Share Earnings over the last 16 years have been positive in 6 years.

Beam Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BEAM
CUSIP: 07373V
Website: beamtx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.89
Quick Ratio: 5.79

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BEAM Technical Analysis vs Fundamental Analysis

Sell
30
Beam Therapeutics (BEAM) is a Sell

Is Beam Therapeutics a Buy or a Sell?

  • Beam Therapeutics stock is rated a Sell
    The current Beam Therapeutics [BEAM] share price is $24.10. The Score for BEAM is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.